HK1217499A1 - 蛋白的多聚形式 - Google Patents

蛋白的多聚形式

Info

Publication number
HK1217499A1
HK1217499A1 HK16105402.3A HK16105402A HK1217499A1 HK 1217499 A1 HK1217499 A1 HK 1217499A1 HK 16105402 A HK16105402 A HK 16105402A HK 1217499 A1 HK1217499 A1 HK 1217499A1
Authority
HK
Hong Kong
Prior art keywords
nox
proteins
polymeric forms
polymeric
forms
Prior art date
Application number
HK16105402.3A
Other languages
English (en)
Inventor
Gregory Kapp
Laura Serwer
Moan Natacha Le
Stephen P L Cary
Original Assignee
Omniox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omniox Inc filed Critical Omniox Inc
Publication of HK1217499A1 publication Critical patent/HK1217499A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
HK16105402.3A 2013-01-07 2016-05-11 蛋白的多聚形式 HK1217499A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/020602 WO2014107171A1 (en) 2013-01-07 2013-01-07 Polymeric forms of h-nox proteins

Publications (1)

Publication Number Publication Date
HK1217499A1 true HK1217499A1 (zh) 2017-01-13

Family

ID=51062401

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105402.3A HK1217499A1 (zh) 2013-01-07 2016-05-11 蛋白的多聚形式

Country Status (10)

Country Link
US (5) US10385116B2 (zh)
EP (2) EP2941440B1 (zh)
JP (1) JP6322652B2 (zh)
CN (2) CN105408354B (zh)
AU (3) AU2013204158B2 (zh)
CA (1) CA2897018C (zh)
ES (1) ES2886531T3 (zh)
HK (1) HK1217499A1 (zh)
NZ (1) NZ709825A (zh)
WO (1) WO2014107171A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105408354B (zh) 2013-01-07 2020-09-18 欧姆尼奥克斯公司 H-nox蛋白的多聚形式
WO2014193963A1 (en) * 2013-05-28 2014-12-04 The Johns Hopkins University Controlled outgassing of hyberbarically loaded materials for the delivery of oxygen and other therapeutic gases in biomedical applications
CA2979974A1 (en) * 2015-03-17 2016-09-22 Omniox, Inc. Modulation of tumor immunity by protein-mediated o2 delivery
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
CA3014651A1 (en) * 2016-02-16 2017-08-24 Omniox, Inc. Modulation of hypoxia associated with stroke
WO2018044866A1 (en) 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
IL280536B1 (en) * 2018-08-02 2024-08-01 Dyne Therapeutics Inc Muscle oriented clasps and their uses
EP3836911A1 (en) * 2018-08-15 2021-06-23 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
KR20220032568A (ko) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
KR20220085796A (ko) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
EP4081305B1 (en) 2019-12-24 2024-09-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
AU2021264550A1 (en) 2020-05-01 2022-11-17 Gilead Sciences, Inc. CD73 inhibiting 2,4-dioxopyrimidine compounds
JP6974808B1 (ja) * 2021-02-10 2021-12-01 株式会社タンガロイ 切削インサート
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022305241A1 (en) * 2021-07-01 2024-01-25 Bluebird Bio, Inc. Methods
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA138006A (en) 1911-05-01 1912-01-23 John G. Elbs Egg carrier
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5248766A (en) 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
US5776898A (en) 1991-05-14 1998-07-07 Dana-Farber Cancer Institute Method for treating a tumor with a chemotherapeutic agent
WO1992020369A1 (en) 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
AU735799C (en) 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
US5981710A (en) 1997-07-21 1999-11-09 Baxter International, Inc. Therapeutic hemoglobin composition having isotropically increased size
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
EP1850852A4 (en) 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE
PT1981519T (pt) 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
DK2463297T3 (en) * 2006-05-22 2017-01-09 Univ California Oxygen Compositions and Methods
US20110300113A1 (en) 2006-09-19 2011-12-08 Deutsches Krebsforschungszentrum Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro
JP2010513405A (ja) 2006-12-21 2010-04-30 ノボ・ノルデイスク・エー／エス 二量体プロラクチンレセプターリガンド
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
US8742073B2 (en) 2010-05-27 2014-06-03 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20140363496A1 (en) 2011-01-07 2014-12-11 Vindico NanoBio Technology Inc. Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
PT2661275T (pt) 2011-01-07 2019-04-24 Poseida Therapeutics Inc Composições e métodos para a entrega a tumores de agentes ligantes de elevada afinidade para o oxigénio
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
CN105408354B (zh) 2013-01-07 2020-09-18 欧姆尼奥克斯公司 H-nox蛋白的多聚形式
AU2015358413A1 (en) 2014-12-05 2017-06-29 Poseida Therapeutics, Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
CA2979974A1 (en) * 2015-03-17 2016-09-22 Omniox, Inc. Modulation of tumor immunity by protein-mediated o2 delivery
CA3014651A1 (en) * 2016-02-16 2017-08-24 Omniox, Inc. Modulation of hypoxia associated with stroke

Also Published As

Publication number Publication date
ES2886531T3 (es) 2021-12-20
CA2897018A1 (en) 2014-07-10
US10385116B2 (en) 2019-08-20
NZ709825A (en) 2019-08-30
BR112015016299A2 (pt) 2022-01-25
CN112062861A (zh) 2020-12-11
AU2013204158B2 (en) 2016-09-22
AU2016277631B2 (en) 2019-03-21
US11117952B2 (en) 2021-09-14
US20210002351A1 (en) 2021-01-07
JP2016508147A (ja) 2016-03-17
EP3922643A1 (en) 2021-12-15
CN105408354B (zh) 2020-09-18
US20150273024A1 (en) 2015-10-01
US11987614B2 (en) 2024-05-21
US10766947B2 (en) 2020-09-08
AU2016277631A1 (en) 2017-01-19
CN105408354A (zh) 2016-03-16
EP2941440A4 (en) 2016-06-15
JP6322652B2 (ja) 2018-05-09
US20220048977A1 (en) 2022-02-17
CA2897018C (en) 2021-07-27
EP2941440B1 (en) 2021-05-05
AU2013204158A1 (en) 2014-07-24
US20200017574A1 (en) 2020-01-16
WO2014107171A1 (en) 2014-07-10
EP2941440A1 (en) 2015-11-11
AU2019204253A1 (en) 2019-07-04
US20160185839A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
IL284301A (en) Heterodimeric proteins
HK1217499A1 (zh) 蛋白的多聚形式
IL276106A (en) Garp-binding proteins and their uses
SG11201506876XA (en) Modification of polypeptides
DK3041857T3 (da) Protein a-kromatografi
SG11201603028SA (en) Purification of proteins
GB201317802D0 (en) SmartHaler patent application
GB201308658D0 (en) Antibodies
GB201315487D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201302597D0 (en) Novel Synthetic Proteins
IL286537A (en) Synthetic proteins that assemble themselves
BR112016010457A2 (pt) Modificação de poliamidas
GB201308057D0 (en) Protein
GB201401955D0 (en) Protein
EP2978770A4 (en) REINFORCEMENT OF PROTEINS
GB201314945D0 (en) Protein crystals
HK1198422A1 (zh) 羊毛固醇三萜的新穎用途
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein
HUP1300278A2 (en) Ski-truck made of rubber
ES1098808Y (es) Juguete-instrumento de muneco bailarin
PT2991505T (pt) Enriquecimento de proteína
GB201304608D0 (en) BenTime of Yisrael operable arrangement
GB201318284D0 (en) Construction of surfaces